<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172818">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846352</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00007668</org_study_id>
    <nct_id>NCT00846352</nct_id>
  </id_info>
  <brief_title>Early Versus Late Bronchoscopy in Bone Marrow Transplantation (BMT) Patients</brief_title>
  <official_title>Randomized Trial Comparing Early Versus Late Bronchoscopy in Hematopoietic Stem Cell Transplant Patients With Pulmonary Infiltrates.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the outcomes of bronchoscopy in Bome Marrow Transplant (BMT)
      patients who develop lung infiltrates suspicious for infections of the lungs. It will
      consist of two groups, one group will receive bronchoscopy within thirty six hours of
      enrollment, while the other group will receive bronchoscopy five days after enrollment. The
      purpose of this study is to determine the ideal time for bronchoscopy in this group of
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At this time there exist no studies that help Pulmonologists and Oncologists decide on the
      best time to perform diagnostic bronchoscopies in Bone Marrow Transplant patients with
      suspected pulmonary infections. Practice patterns vary from institution to institution and
      also vary widely within an institution based on the practice preferences of the attending
      physicians. This study is a prospective randomized trial comparing early ( within 24-36
      hours of enrollment) to late ( day 5-6 after enrollment) bronchoscopy in Bone Marrow
      Transplant patients who develop pulmonary infiltrates or clinical evidence of respiratory
      infection. If patients in the late arm require earlier bronchoscopy or do not require
      bronchoscopy on day 5-6 then the care will be dictated by the attending physician. Only
      bronchoscopies that are clinically indicated will be performed.

      The aim is to determine the optimal timing for performing bronchoscopy in this group of
      patients. The primary outcomes will be change of therapy as determined by addition or
      removal of antibiotics, antifungals, antivirals or steroids etc. as well as the oncologist's
      opinion on the impact the bronchoscopic results had on care of the patient. Patients will be
      followed throughout their hospitalization as well as receive a phone call 3 months after
      hospital discharge. Written consent will be obtained from the patients or health care power
      of attorney in relevant cases.

      It is our hope that the results of this study will help better define the role of
      bronchoscopy in the management of Bone Marrow Transplant patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in therapy due to results obtained from bronchoscopy.</measure>
    <time_frame>When results of bronchoscopy are available</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-Hospital and three month mortality</measure>
    <time_frame>Three months from time of enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic therapy</measure>
    <time_frame>Variable</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bone Marrow Transplantation</condition>
  <arm_group>
    <arm_group_label>Early Bronch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive bronchoscopy within 36 hours of enrollment into the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late bronch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive bronchoscopy within 5 days of enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Variation in the time for performing bronchoscopy</intervention_name>
    <description>The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).</description>
    <arm_group_label>Early Bronch</arm_group_label>
    <arm_group_label>Late bronch</arm_group_label>
    <other_name>Bronchoscopy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who have had allogenic or autologous HSCT who are admitted to the BMT,
             and felt to need bronchoscopy by their physician.

        Exclusion Criteria:

          -  Active hemoptysis, allergies to topical and IV anesthetics with no appropriate
             substitutes available. Being on non-invasive positive pressure ventilation that would
             not allow for safe bronchoscopy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F Conforti, D.O</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali S Wahla, M.D</last_name>
    <phone>336-716-3182</phone>
    <email>awahla@wfubmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John F Conforti, D.O</last_name>
    <phone>336-716-4649</phone>
    <email>jconfort@wfubmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark R Bowling, M.D</last_name>
      <phone>601-815-2005</phone>
      <email>mbowling@medicine.umsmed.edu</email>
    </contact>
    <investigator>
      <last_name>Mark R Bowling, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali S Wahla, M.D</last_name>
      <phone>336-716-3182</phone>
      <email>awahla@wfubmc.edu</email>
    </contact>
    <investigator>
      <last_name>John F Conforti, D.O</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali S Wahla, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Hurd, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arjun Chatterjee, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kirk Depriest, D.O</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin High, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Wood, M.D</last_name>
      <phone>614-293-4925</phone>
      <email>Karen.Wood@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer McCallister, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation. 1997 Apr 27;63(8):1079-86.</citation>
    <PMID>9133468</PMID>
  </reference>
  <reference>
    <citation>Krowka MJ, Rosenow EC 3rd, Hoagland HC. Pulmonary complications of bone marrow transplantation. Chest. 1985 Feb;87(2):237-46. Review.</citation>
    <PMID>2981658</PMID>
  </reference>
  <reference>
    <citation>Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, Frei E 3rd, Antman KH. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplant. 1992 Jul;10(1):57-63.</citation>
    <PMID>1515880</PMID>
  </reference>
  <reference>
    <citation>Rañó A, Agustí C, Jimenez P, Angrill J, Benito N, Danés C, González J, Rovira M, Pumarola T, Moreno A, Torres A. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures. Thorax. 2001 May;56(5):379-87.</citation>
    <PMID>11312407</PMID>
  </reference>
  <reference>
    <citation>White P, Bonacum JT, Miller CB. Utility of fiberoptic bronchoscopy in bone marrow transplant patients. Bone Marrow Transplant. 1997 Oct;20(8):681-7.</citation>
    <PMID>9383232</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 5, 2009</lastchanged_date>
  <firstreceived_date>February 2, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Dr. John Conforti</name_title>
    <organization>Wake Forest University Baptist Medical Center</organization>
  </responsible_party>
  <keyword>Bone Marrow Transplantation</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Bronchoscopy</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
